Tình trạng thụ thể hormone và c-ERBB2 trong ung thư vú di căn xa và tái phát tại chỗ
Tóm tắt
Thụ thể estrogen (ER), thụ thể progesterone (PR) và c-ERBB2 (HER2/neu) là những dấu hiệu quan trọng trong điều trị và tiên lượng trong việc quản lý ung thư vú. Những dấu hiệu này không phải lúc nào cũng được phân tích trong các ca ung thư vú di căn xa và tái phát tại chỗ. Chúng tôi đã so sánh sự biểu hiện miễn dịch mô học trong một loạt ung thư vú nguyên phát với các sự di căn xa của chúng (n = 72) và các tái phát cục bộ (n = 45) và phân tích ảnh hưởng của bất kỳ thay đổi nào đến sự sống sót. Tỷ lệ không nhất quán giữa tình trạng nguyên phát và di căn cũng như giữa tình trạng nguyên phát và tái phát tại chỗ lần lượt là 18% (13/72) và 13% (6/45) đối với ER, 42% (30/72) và 33% (15/45) đối với PR, và 7% (5/72) và 2% (1/45) đối với c-ERBB2. Có sự không nhất quán có ý nghĩa thống kê giữa tình trạng PR nguyên phát và di căn (P = .017; κ = 0.201). Trong số các khối u tái phát tại chỗ, 15 (33%) trong số 45 trường hợp đã cho thấy sự không nhất quán đối với PR (P = .006; κ = 0.366). Chúng tôi quan sát thấy một xu hướng sống sót ngắn hơn ở những phụ nữ có khối u di căn và tái phát tại chỗ là ER-neg, không phân biệt với tình trạng ER của khối u nguyên phát. Những phát hiện của chúng tôi gợi ý rằng việc đánh giá định kỳ tình trạng của ER, PR, và c-ERBB2 trong ung thư vú di căn xa và tái phát tại chỗ sẽ có lợi cho các mục đích điều trị và tiên lượng.
Từ khóa
#Thụ thể estrogen #thụ thể progesterone #c-ERBB2 #ung thư vú #di căn xa #tái phát tại chỗ #tiên lượngTài liệu tham khảo
Thike, 2001, Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters, Pathology, 33, 21, 10.1080/00313020123290
Kiang, 1977, Factors affecting estrogen receptors in breast cancer, Cancer, 40, 1571, 10.1002/1097-0142(197710)40:4<1571::AID-CNCR2820400429>3.0.CO;2-5
Chen, 1995, Estrogen receptor determinations of cutaneous recurrences of breast cancers: reduced sensitivity of hormone binding assays, Breast, 1, 107, 10.1111/j.1524-4741.1995.tb00227.x
Diaz, 2005, Estrogen receptor analysis for breast cancer, current issues and keys to increasing testing accuracy, Adv Anat Pathol, 12, 10, 10.1097/00125480-200501000-00003
Desombre, 1980, Estrophilin assays in breast cancer: quantitative features and application to the mastectomy specimen, Cancer, 46, 2783, 10.1002/1097-0142(19801215)46:12+<2783::AID-CNCR2820461408>3.0.CO;2-4
Sunderland, 1991, Hormones and breast cancer, Trends Endocrinol Metab, 2, 72, 10.1016/1043-2760(91)90044-N
Skinner, 1980, The clinical value of multiple steroid receptor assays in breast cancer management, Cancer, 4, 2939, 10.1002/1097-0142(19801215)46:12+<2939::AID-CNCR2820461440>3.0.CO;2-5
Osborne, 1980, The value of estrogen and progesterone receptors in the treatment of breast cancer, Cancer, 6, 2884, 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U
Rhodes, 2006, Invited review: oestrogen receptors and breast cancer, Biomed Scientist, 11, 1055
Muss, 1994, c-erb B2 expression and response to adjuvant therapy in women with node positive early breast cancer, N Engl J Med, 330, 1260, 10.1056/NEJM199405053301802
Ross, 1998, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, Stem Cells, 16, 413, 10.1002/stem.160413
Ross, 2003, The HER-2/neu gene and protein in breast cancer: biomarker and target for therapy, Oncologist, 8, 307, 10.1634/theoncologist.8-4-307
Nahta, 2003, Growth factor receptors in breast cancer: potential for therapeutic intervention, Oncologist, 8, 5, 10.1634/theoncologist.8-1-5
Balcerczak, 2003, p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging, J Exp Clin Cancer Res, 22, 247
Ridolfi, 2000, HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach, Mod Pathol, 13, 866, 10.1038/modpathol.3880154
Simon, 2001, Patterns of HER-2 amplification and overexpression in primary and metastatic breast cancer, J Natl Cancer Inst, 93, 1141, 10.1093/jnci/93.15.1141
Mobbs, 1986, Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment, Eur J Cancer Clin Oncol, 23, 819, 10.1016/0277-5379(87)90285-9
Santinelli, 2008, HER-2 status discrepancy between primary breast cancer and metastatic sites: impact on target therapy, Int J Cancer, 122, 999, 10.1002/ijc.23051
Masood, 2000, Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study, Ann Clin Lab Sci, 30, 259
Shimizu, 2000, c-erb B2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues, J Surg Oncol, 73, 17, 10.1002/(SICI)1096-9098(200001)73:1<17::AID-JSO5>3.0.CO;2-2
Cardoso, 2001, Evaluation of HER-2, p53, bcl2, topoisomerase IIα, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes, Ann Oncol, 12, 615, 10.1023/A:1011182524684
Lacroix, 1989, Overexpression of erbB2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases, Oncogene, 4, 145
Iglehart, 1990, Increased cerb-B2 gene copies and expression in multiple stages of breast cancer, Cancer Res, 50, 6701
Tanner, 2001, Amplification of HER-2/neu and topoisomerase II-α in primary and metastatic breast cancer, Cancer Res, 61, 5345
Symmans, 1995, Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions, Hum Pathol, 26, 210, 10.1016/0046-8177(95)90039-X
Early Breast Cancer Trialists’ Collaborative Group, 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4
Allred, 2008, Problems and solutions in the evaluation of hormone receptors in breast cancer, J Clin Oncol, 28, 2434
Tilley, 1978, Inter-site variation of estrogen receptors in human breast cancers, Br J Cancer, 38, 544, 10.1038/bjc.1978.242
Hull, 1983, Multiple estrogen receptor assays in human breast cancer, Cancer Res, 43, 413
Gross, 1984, Multiple progesterone receptor assays in human breast cancer, Cancer Res, 44, 836
Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106
Tsuda, 1989, Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1, Cancer Res, 49, 3104
Brennan, 1979, The variability of estrogen receptors in metastatic breast cancer, Am J Surg, 137, 260, 10.1016/0002-9610(79)90159-4
Lower, 2005, Impact of metastatic estrogen receptor and progesterone receptor status on survival, Breast Cancer Res Treat, 90, 65, 10.1007/s10549-004-2756-z
Gancberg, 2002, Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites, Ann Oncol, 13, 1036, 10.1093/annonc/mdf252
Sekido, 2003, Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER-2 gene amplification and p35 mutation, Int J Oncol, 22, 1225
Holdaway, 1983, Variation in receptor status between primary and metastatic breast cancer, Cancer, 52, 479, 10.1002/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O
Rosen, 1977, Estrogen receptor protein in multiple tumour specimens from individual patients with breast cancer, Cancer, 39, 2194, 10.1002/1097-0142(197705)39:5<2194::AID-CNCR2820390537>3.0.CO;2-Y
Kuukasjärvi, 1996, Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy, J Clin Oncol, 14, 2584, 10.1200/JCO.1996.14.9.2584
Benjamin, 1994, Estrogen and progesterone receptor concordance between primary and recurrent breast cancer, J Surg Oncol, 57, 71, 10.1002/jso.2930570202
Paridaens, 1980, Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer, Cancer, 46, 2889, 10.1002/1097-0142(19801215)46:12+<2889::AID-CNCR2820461430>3.0.CO;2-4
Nomura, 1985, Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer, Cancer, 55, 546, 10.1002/1097-0142(19850201)55:3<546::AID-CNCR2820550313>3.0.CO;2-V
Zidan, 2005, Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease, Br J Cancer, 93, 552, 10.1038/sj.bjc.6602738
Tapia, 2007, HER2 gene status in primary breast cancers and matched distant metastases, Breast Cancer Res, 9, R31, 10.1186/bcr1676
Leake, 1997, Prediction of hormone sensitivity: the receptor years and onwards, Endocr Relat Cancer, 4, 289, 10.1677/erc.0.0040289
Cui, 2005, Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy, J Clin Oncol, 23, 7721, 10.1200/JCO.2005.09.004
Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101
Niehans, 1993, Stability of HER-2/neu expression over time and at multiple metastatic sites, J Natl Cancer Inst, 85, 1230, 10.1093/jnci/85.15.1230
Edgerton, 2003, erbB-2 (HER-2) and breast cancer progression, Appl Immunohistochem Mol Morphol, 11, 214, 10.1097/00129039-200309000-00003
Teixeira, 1995, Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients, Int J Cancer, 63, 63, 10.1002/ijc.2910630113
Pandis, 1995, Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups, Genes Chromosomes Cancer, 12, 173, 10.1002/gcc.2870120304
Trent, 1993, Clonal chromosome abnormalities in human breast carcinoma, II: thirty-four cases with metastatic disease, Genes Chromosomes Cancer, 7, 194, 10.1002/gcc.2870070403
Kuukasjärvi, 1997, Genetic heterogeneity and clonal evolution underlying development of asynchronous metastases in human breast cancer, Cancer Res, 57, 1597